Analyst Ratings For Genmab
Analyst Ratings For Genmab
Genmab 的分析師評級
Across the recent three months, 6 analysts have shared their insights on Genmab (NASDAQ:GMAB), expressing a variety of opinions spanning from bullish to bearish.
在最近三個月中，有6位分析師分享了他們對Genmab（納斯達克股票代碼：GMAB）的見解，表達了從看漲到看跌的各種觀點。
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
下表彙總了他們最近的評級，闡明瞭過去30天內情緒的變化，並將其與前幾個月進行了比較。
The 12-month price targets, analyzed by analysts, offer insights with an average target of $49.67, a high estimate of $50.00, and a low estimate of $48.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 0.16%.
分析師分析的12個月目標股價提供了見解，平均目標價爲49.67美元，最高估計爲50.00美元，低估值爲48.00美元。隨着分析師將平均目標股價下調了0.16％，情緒的負面轉變顯而易見。
Exploring Analyst Ratings: An In-Depth Overview
探索分析師評級：深入概述
The standing of Genmab among financial...
通過對分析師...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。